Canadian Journal of Gastroenterology and Hepatology

Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk


Publishing date
01 Oct 2018
Status
Published
Submission deadline
25 May 2018

1University of P.J. Šafárik, Košice, Slovakia

2Mansoura University, Mansoura, Egypt

3Medical University of Bialystok, Białystok, Poland

4Halberg Hospital and Research Institute, Moradabad, India


Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk

Description

Chronic hepatitis C is associated with elevated risk of metabolic syndrome, particularly insulin resistance, liver steatosis, and type 2 diabetes mellitus (T2DM). Indeed, T2DM is considered to be an extrahepatic manifestation of chronic hepatitis C virus infection. Its prevalence in hepatitis C patients is multiple times higher than in general population, mainly in patients that do not respond to interferon based treatment and in patients with advanced liver fibrosis or cirrhosis. Patients with chronic hepatitis C have higher cardiovascular risk compared to general population and accelerated atherosclerosis is also considered to be an extrahepatic manifestation of chronic hepatitis C.

Multiple studies have described highly variable correlations between chronic hepatitis B on one hand and metabolic syndrome, nonalcoholic fatty liver, and dyslipidemia on the other. This association extends both ways, as metabolic syndrome, dyslipidemia, or T2DM worsens the clinical course and outcomes of chronic hepatitis B and C by acceleration of fibrogenesis and increasing the risk of cirrhosis and hepatocellular cancer (HCC). No association between chronic hepatitis B and diabetes mellitus has been described as of now. Patients with chronic hepatitis C and metabolic syndrome have achieved sustained virologic response (SVR) less frequently and if achieved, SVR has lowered the risk of T2DM in the future. The treatment of chronic hepatitis C by direct acting antivirals not only has led to the SVR in almost all of the treated patients but also has lowered glycemia, particularly in T2DM patients, and has improved fasting hyperglycemia. This treatment has also led to the decrease of the levels of triglycerides in patients with hypertriglyceridemia. Retrospective studies have shown that statin treatment reduces the risk for HCC in patients with chronic hepatitis B and C.

We especially welcome scientists to contribute original research articles and clinical studies as well as review articles describing the current state of the art in the field of chronic viral hepatitis and metabolic syndrome/cardiovascular risk. This special issue aims to attract both practitioners and researchers in the areas of hepatology, gastroenterology, infectious diseases, cardiology, diabetology, clinical virology, and internal medicine.

Potential topics include but are not limited to the following:

  • Prevalence of metabolic syndrome, T2DM, prediabetes, or dyslipidemia in chronic hepatitis B
  • Prevalence of metabolic syndrome, T2DM, prediabetes, or dyslipidemia in chronic hepatitis C
  • Associations between metabolic syndrome and risk of HCC in patients with chronic viral hepatitis B or C
  • Influence of metabolic syndrome, T2DM, prediabetes, or dyslipidemia on the clinical course of chronic hepatitis B or C
  • Associations between cardiovascular risk and chronic hepatitis B or C
  • Influence of statins administration on the pathogenesis, clinical course, and outcomes of chronic hepatitis B or C
  • Influence of DAAs treatment on metabolic syndrome and its components in chronic hepatitis C

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 7369314
  • - Editorial

Chronic Viral Hepatitis and Metabolic Syndrome/Cardiovascular Risk

Peter Jarcuska | Ahmed Abdel-Razik | ... | Ram B. Singh
  • Special Issue
  • - Volume 2018
  • - Article ID 6095097
  • - Research Article

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

Sylvia Drazilova | Martin Janicko | ... | Peter Jarcuska
  • Special Issue
  • - Volume 2018
  • - Article ID 9151820
  • - Research Article

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy

Tommaso Stroffolini | Evangelista Sagnelli | ... | Piero Luigi Almasio
  • Special Issue
  • - Volume 2018
  • - Article ID 8490242
  • - Research Article

Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome

Sanda Mustapic | Sead Ziga | ... | Ivica Grgurevic
  • Special Issue
  • - Volume 2018
  • - Article ID 6150861
  • - Review Article

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy

Sylvia Drazilova | Jakub Gazda | ... | Peter Jarcuska
  • Special Issue
  • - Volume 2018
  • - Article ID 3870454
  • - Research Article

Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children

Marta Flisiak-Jackiewicz | Anna Bobrus-Chociej | ... | Dariusz Marek Lebensztejn
Canadian Journal of Gastroenterology and Hepatology
 Journal metrics
Acceptance rate26%
Submission to final decision79 days
Acceptance to publication42 days
CiteScore2.800
Impact Factor2.055
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.